Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review
The immune checkpoint inhibitor (ICI), anti-programmed cell death receptor-1 (PD-1) antibody, has gained widespread approval for treating various malignancies. Among the immune-related adverse reactions (irAEs) during ICI treatment, the lichenoid reaction is noteworthy. Sintilimab, a new PD-1 inhibi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1276788/full |
| _version_ | 1797393426375770112 |
|---|---|
| author | Shuting Zhou Zhenyu Zhang Xiaodong Feng Chengjian Zhao Lu Jiang |
| author_facet | Shuting Zhou Zhenyu Zhang Xiaodong Feng Chengjian Zhao Lu Jiang |
| author_sort | Shuting Zhou |
| collection | DOAJ |
| description | The immune checkpoint inhibitor (ICI), anti-programmed cell death receptor-1 (PD-1) antibody, has gained widespread approval for treating various malignancies. Among the immune-related adverse reactions (irAEs) during ICI treatment, the lichenoid reaction is noteworthy. Sintilimab, a new PD-1 inhibitor, has secured approval in China for treating refractory non-Hodgkin’s lymphoma, and phase I/II clinical trials for other solid tumors are ongoing both domestically and abroad. This paper presents a case of a mucocutaneous lichenoid reaction associated with sintilimab therapy, its diagnosis, and management. Our study, using multiplex immunofluorescence staining, reveals localized infiltration of CD4+ and CD8+ T lymphocytes in the subepithelial lamina propria region with upregulated PD-1 expression, implying an association between PD-1 expression upregulation and lichenoid reactions provoked by PD-1 monoclonal antibody. We provide a summary of clinical characteristics and treatment guidelines for lichenoid reactions induced by ICIs from previous reports, highlighting the success of a combined therapeutic regimen of oral antihistamines and topical corticosteroids in controlling symptoms without interrupting ICI treatment. |
| first_indexed | 2024-03-09T00:03:22Z |
| format | Article |
| id | doaj.art-ccabe5ebe6c049d0952309c06a65c42c |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-03-09T00:03:22Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-ccabe5ebe6c049d0952309c06a65c42c2023-12-12T15:54:27ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122023-12-011410.3389/fphar.2023.12767881276788Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and reviewShuting Zhou0Zhenyu Zhang1Xiaodong Feng2Chengjian Zhao3Lu Jiang4State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, Department of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, ChinaState Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, Department of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, ChinaState Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, Department of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, ChinaState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan, ChinaState Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Chinese Academy of Medical Sciences Research Unit of Oral Carcinogenesis and Management, Department of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, ChinaThe immune checkpoint inhibitor (ICI), anti-programmed cell death receptor-1 (PD-1) antibody, has gained widespread approval for treating various malignancies. Among the immune-related adverse reactions (irAEs) during ICI treatment, the lichenoid reaction is noteworthy. Sintilimab, a new PD-1 inhibitor, has secured approval in China for treating refractory non-Hodgkin’s lymphoma, and phase I/II clinical trials for other solid tumors are ongoing both domestically and abroad. This paper presents a case of a mucocutaneous lichenoid reaction associated with sintilimab therapy, its diagnosis, and management. Our study, using multiplex immunofluorescence staining, reveals localized infiltration of CD4+ and CD8+ T lymphocytes in the subepithelial lamina propria region with upregulated PD-1 expression, implying an association between PD-1 expression upregulation and lichenoid reactions provoked by PD-1 monoclonal antibody. We provide a summary of clinical characteristics and treatment guidelines for lichenoid reactions induced by ICIs from previous reports, highlighting the success of a combined therapeutic regimen of oral antihistamines and topical corticosteroids in controlling symptoms without interrupting ICI treatment.https://www.frontiersin.org/articles/10.3389/fphar.2023.1276788/fulllichenoid reactionsSintilimab Therapyimmune checkpoint inhibitors (ICIs)PD-1 inhibitormucocutaneous reactionsimmune-related adverse events (irAEs) |
| spellingShingle | Shuting Zhou Zhenyu Zhang Xiaodong Feng Chengjian Zhao Lu Jiang Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review Frontiers in Pharmacology lichenoid reactions Sintilimab Therapy immune checkpoint inhibitors (ICIs) PD-1 inhibitor mucocutaneous reactions immune-related adverse events (irAEs) |
| title | Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review |
| title_full | Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review |
| title_fullStr | Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review |
| title_full_unstemmed | Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review |
| title_short | Lichenoid mucocutaneous reactions associated with sintilimab therapy in a non-small cell lung adenocarcinoma patient: case report and review |
| title_sort | lichenoid mucocutaneous reactions associated with sintilimab therapy in a non small cell lung adenocarcinoma patient case report and review |
| topic | lichenoid reactions Sintilimab Therapy immune checkpoint inhibitors (ICIs) PD-1 inhibitor mucocutaneous reactions immune-related adverse events (irAEs) |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2023.1276788/full |
| work_keys_str_mv | AT shutingzhou lichenoidmucocutaneousreactionsassociatedwithsintilimabtherapyinanonsmallcelllungadenocarcinomapatientcasereportandreview AT zhenyuzhang lichenoidmucocutaneousreactionsassociatedwithsintilimabtherapyinanonsmallcelllungadenocarcinomapatientcasereportandreview AT xiaodongfeng lichenoidmucocutaneousreactionsassociatedwithsintilimabtherapyinanonsmallcelllungadenocarcinomapatientcasereportandreview AT chengjianzhao lichenoidmucocutaneousreactionsassociatedwithsintilimabtherapyinanonsmallcelllungadenocarcinomapatientcasereportandreview AT lujiang lichenoidmucocutaneousreactionsassociatedwithsintilimabtherapyinanonsmallcelllungadenocarcinomapatientcasereportandreview |